Precipio IncPRPO
▲ PositiveCapitalrelevance
Q2 revenue up 22.8%, adjusted EBITDA positive, and cash balance increased.
Impact on stocks 1
Biotech & Genomic Medicine
Precipio IncPrecipio announced its Q2 2026 financial results, with revenue of $7 million, a 22.8% increase year-over-year. Adjusted EBITDA was $0.4 million, compared to a loss of $0.2 million in Q1 2026. Cash flow from operations was $0.7 million, and total cash increased by $0.5 million, bringing the quarter-end cash balance to over $3 million, up from $1.1 million in Q2 2025.
Precipio IncQ2 revenue up 22.8%, adjusted EBITDA positive, and cash balance increased.